SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-048671
Filing Date
2024-04-26
Accepted
2024-04-26 08:30:09
Documents
7
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A 2024_proxy_statement.htm DEF 14A 606546
2 GRAPHIC img261556127_0.jpg GRAPHIC 39464
3 GRAPHIC img261556127_1.jpg GRAPHIC 19035
4 GRAPHIC img261556127_2.jpg GRAPHIC 39464
5 GRAPHIC img261556127_3.jpg GRAPHIC 19035
6 GRAPHIC img261556127_4.jpg GRAPHIC 1398515
7 GRAPHIC img261556127_5.jpg GRAPHIC 414899
  Complete submission text file 0000950170-24-048671.txt   3264222
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-41551 | Film No.: 24878978
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)